Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology  |  Pediatrics/Neonatology

Search Medical Condition
Please enter condition
Please choose location

Leukemia (Pediatric) Clinical Trials

A listing of Leukemia (Pediatric) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (90) clinical trials

Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine Busulfan and Total Body Irradiation (TBI)

Conventional allogeneic hematopoietic cell transplantation (HCT) for patients with hematological malignancies involves conditioning with high doses of systemic chemo/radiation therapy such as cyclophosphamide (CY) plus 1200 or 1000 cGy total body irradiation (TBI; CY/TBI) or busulfan (Bu) / CY (BuCy). Unfortunately, such regimens have been associated with significant toxicities, limiting ...

Phase

The GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia

The modification includes: 1. In the induction phase, the agent of dexamethasone 6 mg/m2 is used instead of prednisone after prednisone prophase. 2. The phase "CAM" is 2 weeks for SR patients and 4 weeks for IR and HR patients,respectively. 3. Both the SR and IR treatments involve the protocol ...

Phase

High-Dose Methotrexate (MTX) for Adult Acute Lymphoblastic Leukemia (ALL)

Although the multi-agent chemotherapies in current use produce complete remission for a majority of patients with acute lymphoblastic leukemia (ALL), the prognosis for adult ALL remains discouraging due to a high incidence of relapse. Optimal post-remission therapy, therefore, has been a matter of vital concern. In some pediatric ALL studies, ...

Phase

Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)

The prognosis for adult acute lymphoblastic leukemia (ALL) remains poor, which contrasts with that for pediatric ALL. It is regarded that the prognostic diversity is attributable to several differences between adults and children with respect to biological characteristics of leukemic cells, tolerance to anticancer drugs, treatment itself, and so on. ...

Phase

Studies on the Significance of CXCR4-CXCL12 on Leukemic Cells Passing Through"Marrow-Blood Barrier"

Bone marrow consists of a complex hematopoietic cellular component that continuously goes through self-replication and/or differentiation processes. When the blood progenitor cells differentiate to mature cells, they will exit unassisted to peripheral blood. On the other hand, the immature cells trapped by marrow-blood barrier. However, malignant transformation of the hematopoietic ...

Phase N/A

Stem Cell Transplant for Hematological Malignancy

Preparative regimen using total body irradiation (TBI) and cyclophosphamide: 1. on day -6 and -5: cyclophosphamide is given, 2. on day -4, -3, -2, and -1: TBI is given, 3. on day 0: stem cell or bone marrow is infused. Alternate preparative therapy for patients not able to receive TBI ...

Phase N/A

Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])

The standard treatment in many disorders of the bone marrow is high dose chemotherapy and whole-body radiation treatment followed by the stem cell transplant. This type of transplant not only suppresses or kills off the immune system, but is very toxic to the bone marrow. This study uses a chemotherapy ...

Phase

Poly(Ethylene Glycol)(PEG)-Asparaginase During Two Treatment Courses

Asparaginase is used in the treatment of childhood lymphoblastic leukemia. Approximately 1/3 of the patients develops blocking antibodies against native E.coli asparaginase during the second exposure, so that they do not benefit from treatment and thus may have a worse prognosis. PEG-asparaginase is less immunogenic so that fewer patients may ...

Phase

Medical Research Council (MRC) Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003

Randomisations Patients will be assigned to MRD risk groups based on day 29 and post consolidation MRD results and randomised as follows: 1. MRD Low Risk Group (MRD negative at day 29 and week 11 or positive <1 x 10-4 at day 28 and negative at week 11) will continue ...

Phase

Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant

Detailed analysis will be performed at preselected time points following therapy by - standard flow cytometry in combination with intracellular cytokine/antigen staining - spectratype analysis - TREC assays

Phase N/A